Haffkine Institute gets govt's approval to produce Bharat Biotech's Covaxin

The approval comes in the backdrop of rising Covid-19 cases and government's effort to increase pace of vaccination
Haffkine Institute, one of India's oldest biomedical research institutes, today received central government nod to produce Bharat Biotech's Covid-19 vaccine Covaxin on a technology transfer basis.

Department of biotechnology's secretary Renu Swarup conveyed the approval to Maharashtra chief secretary Sitaram Kunte on recommendation of an expert committee. 

The approval comes in the backdrop of rising Covid-19 cases and government's effort to increase pace of vaccination through production ramp ups and quicker approvals.

Last month, Maharashtra Chief Minister Uddhav Thackeray had sought central nod to manufacture Bharat Biotech's Covaxin at Haffkine Institute. After a visit to the institute, Thackeray had said a manufacturing plant would be set up in partnership with Bharat Biotech to manufacture vaccines.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel